PDF(Pubmed)
Abstract：
UNASSIGNED: From the beginning of the year 2024, gradually implemented amendment to the Medicines Act will enable interchange of biological medicines in pharmacies in Finland. The legislative change aims to reduce health care costs.
UNASSIGNED: Opinions of the biological medicine users regarding substitution in pharmacies and knowledge about biological medicines were determined by a patient survey in community pharmacies and via patient organizations in Finland.
UNASSIGNED: In total, 199 users of biological medicines responded to the survey. The respondents did not always know which product they were using, an originator or a biosimilar. This was more prominent among patients with biosimilars determined according to brand names. The more recently the biological medicine had been prescribed, the more likely a biosimilar was in use. Only about 40% of the respondents would enable pharmacies to substitute their biological medicine to a lower cost product. The most common obstacle to the idea of interchange in pharmacies was that the respondents wanted to keep the product the doctor had prescribed for them. In general, biosimilar users were more accepting towards possible interchange than originator users.
UNASSIGNED: Although the most recent treatments appear to be initiated with biosimilars, interchange in pharmacies could enable an efficient way to lower health care costs. However, guidance and awareness regarding biosimilars and biological medicines in general would improve patients\' willingness towards the change, but also help pharmacists and prescribing doctors in their meaningful role.
UNASSIGNED: Opinions of the biological medicine users regarding substitution in pharmacies and knowledge about biological medicines were determined by a patient survey in community pharmacies and via patient organizations in Finland.
UNASSIGNED: In total, 199 users of biological medicines responded to the survey. The respondents did not always know which product they were using, an originator or a biosimilar. This was more prominent among patients with biosimilars determined according to brand names. The more recently the biological medicine had been prescribed, the more likely a biosimilar was in use. Only about 40% of the respondents would enable pharmacies to substitute their biological medicine to a lower cost product. The most common obstacle to the idea of interchange in pharmacies was that the respondents wanted to keep the product the doctor had prescribed for them. In general, biosimilar users were more accepting towards possible interchange than originator users.
UNASSIGNED: Although the most recent treatments appear to be initiated with biosimilars, interchange in pharmacies could enable an efficient way to lower health care costs. However, guidance and awareness regarding biosimilars and biological medicines in general would improve patients\' willingness towards the change, but also help pharmacists and prescribing doctors in their meaningful role.
摘要：
■从2024年初开始，逐步实施的《药品法》修正案将使芬兰药房中的生物药品能够互换。立法变更旨在降低医疗保健成本。
■通过社区药房的患者调查和芬兰的患者组织，确定了生物医学使用者关于药房替代和有关生物药物知识的意见。
■总共，199名生物药物使用者对调查做出了回应。受访者并不总是知道他们使用的是哪种产品，发起人或生物仿制药。在根据品牌名称确定的生物仿制药患者中，这一点更为突出。最近开了生物医学处方，使用生物仿制药的可能性就越大。只有大约40%的受访者会让药店用低成本的产品代替他们的生物医药。药房互换想法的最常见障碍是受访者希望保留医生为他们开的产品。总的来说,生物仿制药用户比发起人用户更容易接受可能的交换。
■尽管最近的治疗似乎是从生物仿制药开始的，药房的交换可以有效地降低医疗保健成本。然而,关于生物仿制药和生物药物的指导和认识将提高患者对改变的意愿，而且还帮助药剂师和处方医生发挥有意义的作用。
■通过社区药房的患者调查和芬兰的患者组织，确定了生物医学使用者关于药房替代和有关生物药物知识的意见。
■总共，199名生物药物使用者对调查做出了回应。受访者并不总是知道他们使用的是哪种产品，发起人或生物仿制药。在根据品牌名称确定的生物仿制药患者中，这一点更为突出。最近开了生物医学处方，使用生物仿制药的可能性就越大。只有大约40%的受访者会让药店用低成本的产品代替他们的生物医药。药房互换想法的最常见障碍是受访者希望保留医生为他们开的产品。总的来说,生物仿制药用户比发起人用户更容易接受可能的交换。
■尽管最近的治疗似乎是从生物仿制药开始的，药房的交换可以有效地降低医疗保健成本。然而,关于生物仿制药和生物药物的指导和认识将提高患者对改变的意愿，而且还帮助药剂师和处方医生发挥有意义的作用。
